Safety & Efficacy, AMI Cardiogenic Shock
Efficacy and Safety of all Impella® Use in Japanese Patients With Drug-Resistant Acute HF: Insight From Japan J-PVAD Study
October 27, 2020
1 min read
Junya Ako, MD, presents the interim analysis of data from 819 patients from the Japanese Registry for Percutaneous VAD (J-PVAD). J-PVAD is an investigator initiated, prospective study of ALL Impella use in Japan with the goal to safely and effectively disseminate the use of Impella with appropriate use guidance.
Dr. Ako describes the Impella site qualification and initiation process in Japan and best practices implemented in Japan. These include:
- Early identification of cardiogenic shock and use of Impella
- Pre-PCI Impella initiation
- Use of pulmonary artery catheter (PAC) and hemodynamic-guided decision making
- Minimizing use of inotropes/vasopressors
Dr. Ako reviews Impella efficacy data from Japan, highlighting 77% 30-day survival in Impella treated patients with AMI cardiogenic shock.
Dr. Ako from Kitasato University presented on behalf of the J-PVAD registry investigators.
Related Content
IMP-1760